269 related articles for article (PubMed ID: 9389688)
21. [A pilot study of G-CSF mobilized allogeneic bone marrow cells plus peripheral blood stem cells transplantation for malignant hematological diseases].
Chen Y; Huang X; Xu L; Liu D; Zhang Y; Ren H; Guo N; Lu D
Zhonghua Yi Xue Za Zhi; 2002 Oct; 82(19):1306-9. PubMed ID: 12509932
[TBL] [Abstract][Full Text] [Related]
22. Total Body Irradiation-Based Myeloablative Haploidentical Stem Cell Transplantation Is a Safe and Effective Alternative to Unrelated Donor Transplantation in Patients Without Matched Sibling Donors.
Solomon SR; Sizemore CA; Sanacore M; Zhang X; Brown S; Holland HK; Morris LE; Bashey A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1299-307. PubMed ID: 25797174
[TBL] [Abstract][Full Text] [Related]
23. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies.
Huang XJ; Liu DH; Liu KY; Xu LP; Chen H; Han W; Chen YH; Wang JZ; Gao ZY; Zhang YC; Jiang Q; Shi HX; Lu DP
Bone Marrow Transplant; 2006 Aug; 38(4):291-7. PubMed ID: 16883312
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic peripheral blood progenitor cell transplantation: analysis of short-term engraftment and acute GVHD incidence in 33 cases. allo-PBPCT Spanish Group.
Urbano-Ispizua A; Solano C; Brunet S; Hernández F; Sanz G; Alegre A; Petit J; Besalduch J; Vivancos P; Díaz MA; Moraleda JM; Carreras E; Ojeda E; de la Rubia J; Benet I; Domingo-Albós A; García-Conde J; Rozman C
Bone Marrow Transplant; 1996 Jul; 18(1):35-40. PubMed ID: 8831993
[TBL] [Abstract][Full Text] [Related]
25. Impact of donor age on outcome after allogeneic hematopoietic cell transplantation.
Rezvani AR; Storer BE; Guthrie KA; Schoch HG; Maloney DG; Sandmaier BM; Storb R
Biol Blood Marrow Transplant; 2015 Jan; 21(1):105-12. PubMed ID: 25278458
[TBL] [Abstract][Full Text] [Related]
26. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
[TBL] [Abstract][Full Text] [Related]
27. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor).
Schmitz N; Dreger P; Suttorp M; Rohwedder EB; Haferlach T; Löffler H; Hunter A; Russell NH
Blood; 1995 Mar; 85(6):1666-72. PubMed ID: 7534141
[TBL] [Abstract][Full Text] [Related]
28. A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation: A Phase II Trial.
Koreth J; Kim HT; Lange PB; Bindra B; Reynolds CG; Chammas MJ; Armand P; Cutler CS; Ho VT; Glotzbecker B; Nikiforow S; Ritz J; Blazar BR; Soiffer RJ; Antin JH; Alyea EP
Biol Blood Marrow Transplant; 2015 Nov; 21(11):1907-13. PubMed ID: 26055298
[TBL] [Abstract][Full Text] [Related]
29. Comparison of outcome of allogeneic bone marrow transplantation with and without granulocyte colony-stimulating factor (lenograstim) donor-marrow priming in patients with chronic myelogenous leukemia.
Ji SQ; Chen HR; Wang HX; Yan HM; Pan SP; Xun CQ
Biol Blood Marrow Transplant; 2002; 8(5):261-7. PubMed ID: 12064363
[TBL] [Abstract][Full Text] [Related]
30. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
[TBL] [Abstract][Full Text] [Related]
31. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV.
Remberger M; Naseh N; Aschan J; Barkholt L; LeBlanc K; Svennberg P; Ringdén O
Bone Marrow Transplant; 2003 Jul; 32(2):217-23. PubMed ID: 12838288
[TBL] [Abstract][Full Text] [Related]
32. Comparison of the content and subpopulations of CD3 and CD34 positive cells in bone marrow harvests and G-CSF-mobilized peripheral blood leukapheresis products from healthy adult donors.
Hassan HT; Stockschläder M; Schleimer B; Krüger W; Zander AR
Transpl Immunol; 1996 Dec; 4(4):319-23. PubMed ID: 8972563
[TBL] [Abstract][Full Text] [Related]
33. Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan.
Tomonari A; Iseki T; Ooi J; Takahashi S; Ishii K; Takahashi T; Shindo M; Nagamura F; Uchimaru K; Nagayama H; Shirafuji N; Tojo A; Tani K; Asano S
Int J Hematol; 2002 Nov; 76(4):354-9. PubMed ID: 12463600
[TBL] [Abstract][Full Text] [Related]
34. Allogeneic bone marrow transplantation for chronic myeloid leukemia using HLA identical sibling donors primed with G-CSF.
Chen HR; Ji SQ; Wang HX; Yan HM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2002 Aug; 10(4):340-6. PubMed ID: 12513770
[TBL] [Abstract][Full Text] [Related]
35. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts.
Raiola AM; Dominietto A; di Grazia C; Lamparelli T; Gualandi F; Ibatici A; Bregante S; Van Lint MT; Varaldo R; Ghiso A; Gobbi M; Carella AM; Signori A; Galaverna F; Bacigalupo A
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1573-9. PubMed ID: 24910379
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic peripheral blood stem cell transplantation and early detection of donor engraftment by polymerase chain reaction.
Tzeng CH; Lyou JY; Lin JS; Chen YR; Hu HY; Yung CH; Wang SY; Lee JC
J Formos Med Assoc; 1998 Apr; 97(4):252-60. PubMed ID: 9585676
[TBL] [Abstract][Full Text] [Related]
37. Prophylactic growth factor-primed donor lymphocyte infusion using cells reserved at the time of transplantation after allogeneic peripheral blood stem cell transplantation in patients with high-risk hematologic malignancies.
Sohn SK; Jung JT; Kim DH; Lee NY; Seo KW; Chae YS; Park SW; Kim JG; Suh JS; Lee KB
Cancer; 2002 Jan; 94(1):18-24. PubMed ID: 11815956
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic peripheral blood stem cell transplantation in patients with early-phase hematologic malignancy: a retrospective comparison of short-term outcome with bone marrow transplantation.
Lemoli RM; Bandini G; Leopardi G; Rosti G; Bonini A; Fortuna A; Rondelli D; Mangianti S; Motta MR; Rizzi S; Tassi C; Cavo M; Remiddi C; Curti A; Conte R; Tura S
Haematologica; 1998 Jan; 83(1):48-55. PubMed ID: 9542323
[TBL] [Abstract][Full Text] [Related]
39. Cytokine-mobilized allogeneic peripheral blood stem cell transplants in children result in rapid engraftment and a high incidence of chronic GVHD.
Levine JE; Wiley J; Kletzel M; Yanik G; Hutchinson RJ; Koehler M; Neudorf S
Bone Marrow Transplant; 2000 Jan; 25(1):13-8. PubMed ID: 10654008
[TBL] [Abstract][Full Text] [Related]
40. Influence of transplanted dose of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-mobilized peripheral blood progenitor cells from HLA-identical sibling donors.
Yamasaki S; Henzan H; Ohno Y; Yamanaka T; Iino T; Itou Y; Kuroiwa M; Maeda M; Kawano N; Kinukawa N; Miyamoto T; Nagafuji K; Shimoda K; Inaba S; Hayashi S; Taniguchi S; Shibuya T; Gondo H; Otsuka T; Harada M;
Bone Marrow Transplant; 2003 Sep; 32(5):505-10. PubMed ID: 12942097
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
